Ocular Therapeutix Inc. (OCUL)

4.30
0.01 0.23
NASDAQ : Health Technology
Prev Close 4.31
Open 4.32
Day Low/High 4.18 / 4.34
52 Wk Low/High 2.35 / 7.31
Volume 305.83K
Avg Volume 746.10K
Exchange NASDAQ
Shares Outstanding 47.20M
Market Cap 206.25M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Ocular Therapeutix™ Announces FDA Acceptance Of NDA Resubmission For DEXTENZA™ For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Company's New...

Ocular TherapeutixTM To Present At Three Upcoming Investor Conferences

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at...

Relative Strength Alert For Ocular Therapeutix

Relative Strength Alert For Ocular Therapeutix

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ocular Therapeutix, Inc. Announces Pricing Of Public Offering Of Common Stock

Ocular Therapeutix, Inc. Announces Pricing Of Public Offering Of Common Stock

Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced today the pricing of a registered underwritten public offering of 3,571,429 shares of its common stock at a public offering price of $7.

Ocular Therapeutix, Inc. Announces Public Offering Of Common Stock

Ocular Therapeutix, Inc. Announces Public Offering Of Common Stock

Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced today that it has commenced a registered underwritten public offering of $25 million of shares of its common stock pursuant to a shelf registration statement that was...

Ocular Therapeutix™ Resubmits NDA For DEXTENZA™ For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery

Ocular Therapeutix™ Resubmits NDA For DEXTENZA™ For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has resubmitted a...

Ocular Therapeutix™ Announces Additional Successful Results For Phase 3 Clinical Trial Of DEXTENZA™

Ocular Therapeutix™ Announces Additional Successful Results For Phase 3 Clinical Trial Of DEXTENZA™

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced additional positive...

3 Small Biotechs With Insider Buying

3 Small Biotechs With Insider Buying

Insiders have an edge in this complex sector, so it's worth checking them out.

Ocular Therapeutix Stock Sees Short Interest Increase 16%

Ocular Therapeutix Stock Sees Short Interest Increase 16%

The most recent short interest data has been released for the 12/15/2016 settlement date, which shows a 709,673 share increase in total short interest for Ocular Therapeutix Inc , to 5,109,129, an increase of 16.13% since 11/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Ocular Therapeutix™ Announces Successful Topline Results For Both Inflammation And Pain Primary Efficacy Endpoints From Phase 3 Clinical Trial Of DEXTENZA™

Ocular Therapeutix™ Announces Successful Topline Results For Both Inflammation And Pain Primary Efficacy Endpoints From Phase 3 Clinical Trial Of DEXTENZA™

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced positive topline results...

Short Interest In Ocular Therapeutix Jumps 10.5%

Short Interest In Ocular Therapeutix Jumps 10.5%

The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 425,157 share increase in total short interest for Ocular Therapeutix Inc , to 4,489,561, an increase of 10.46% since 10/14/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Ocular Therapeutix™ To Present At Two Upcoming Investor Conferences

Ocular Therapeutix™ To Present At Two Upcoming Investor Conferences

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.

Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results And Provides Corporate Update

Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results And Provides Corporate Update

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the...

Ocular Therapeutix™ To Hold Third Quarter 2016 Financial Results Conference Call On Wednesday, November 9, 2016

Ocular Therapeutix™ To Hold Third Quarter 2016 Financial Results Conference Call On Wednesday, November 9, 2016

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third...

Ocular Therapeutix™ Strengthens Management Team With The Appointment Of Andy Hurley As Chief Commercial Officer

Ocular Therapeutix™ Strengthens Management Team With The Appointment Of Andy Hurley As Chief Commercial Officer

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Andy...

Ocular Therapeutix (OCUL) Stock Soars on Regeneron Deal

Ocular Therapeutix (OCUL) Stock Soars on Regeneron Deal

Ocular Therapeutix (OCUL) stands to gain $305 million in milestone and royalty payments from its drug development partnership with Regeneron Pharmaceuticals (REGN).

Ocular Therapeutix™ Outlines Development Strategy For Its Sustained Release Intravitreal Depots To Address Serious Retinal Diseases

Ocular Therapeutix™ Outlines Development Strategy For Its Sustained Release Intravitreal Depots To Address Serious Retinal Diseases

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today provided an update on the Company's...

Ocular Therapeutix™ And Regeneron Enter Into Strategic Collaboration To Develop Sustained Release Formulation Of Aflibercept For The Treatment Of Wet AMD And Other Serious Retinal Diseases

Ocular Therapeutix™ And Regeneron Enter Into Strategic Collaboration To Develop Sustained Release Formulation Of Aflibercept For The Treatment Of Wet AMD And Other Serious Retinal Diseases

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has entered into...

Ocular Therapeutix™ Begins Enrollment In First Phase 3 Clinical Trial With OTX-TP (Sustained Release Travoprost) For The Treatment Of Glaucoma And Ocular Hypertension

Ocular Therapeutix™ Begins Enrollment In First Phase 3 Clinical Trial With OTX-TP (Sustained Release Travoprost) For The Treatment Of Glaucoma And Ocular Hypertension

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the enrollment of the...

Short Interest Increases 16.4% For OCUL

Short Interest Increases 16.4% For OCUL

The most recent short interest data has been released for the 08/31/2016 settlement date, which shows a 513,968 share increase in total short interest for Ocular Therapeutix Inc , to 3,649,289, an increase of 16.39% since 08/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Ocular Therapeutix™ To Participate In The Morgan Stanley Global Healthcare Conference

Ocular Therapeutix™ To Participate In The Morgan Stanley Global Healthcare Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.

Today's Weak On High Volume Stock: Ocular Therapeutix (OCUL)

Today's Weak On High Volume Stock: Ocular Therapeutix (OCUL)

Trade-Ideas LLC identified Ocular Therapeutix (OCUL) as a weak on high relative volume candidate

Ocular Therapeutix™ Reports Second Quarter 2016 Financial Results And Provides Corporate Update

Ocular Therapeutix™ Reports Second Quarter 2016 Financial Results And Provides Corporate Update

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the...

These 7 Stocks Under $10 Are Making Big Moves Higher

These 7 Stocks Under $10 Are Making Big Moves Higher

Here's a technical look at how to trade several stocks under $10 making large moves to the upside.

Ocular Therapeutix™ Announces Presentation At The Ophthalmology Innovation Summit (OIS) At The American Society Of Retina Specialists (ASRS)

Ocular Therapeutix™ Announces Presentation At The Ophthalmology Innovation Summit (OIS) At The American Society Of Retina Specialists (ASRS)

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Jonathan Talamo, M.

Ocular Therapeutix (OCL) Stock Soars, FDA: Corrective Actions Address Concerns

Ocular Therapeutix (OCL) Stock Soars, FDA: Corrective Actions Address Concerns

The FDA released a note saying Ocular Therapeutix’s (OCL) corrective actions on drug Dextenza have addressed the agency’s concerns.

Ocular Therapeutix™ Provides Update On NDA For DEXTENZA™ For The Treatment Of Post-Surgical Ocular Pain

Ocular Therapeutix™ Provides Update On NDA For DEXTENZA™ For The Treatment Of Post-Surgical Ocular Pain

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today provided an update on the status of...

Ocular Therapeutix™ To Report Second Quarter 2016 Financial Results

Ocular Therapeutix™ To Report Second Quarter 2016 Financial Results

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report...

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Ocular Therapeutix, Inc. And Advises Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Ocular Therapeutix, Inc. And Advises Investors With Losses To Contact The Firm

Lundin Law PC ( http://lundinlawpc.com/) announces it is investigating claims against Ocular Therapeutix ("Ocular" or the "Company") (Nasdaq: OCUL) concerning possible violations of federal securities laws.

TheStreet Quant Rating: D- (Sell)